Olon Completes Acquisition of Indian API Plant
25th April 2019
Italian API contract development and manufacturing organization (CDMO) and generics supplier Olon has closed the acquisition of a generics API manufacturing facility in Mahad, India. Financial details were not disclosed.
With this acquisition, Olon said it has successfully finalized its three-year development plan and will now move to its next target, which is to play an important role in manufacturing biologics APIs.
In mid-2017, the Milan-headquartered company also bought Ricerca Biosciencies’ chemical division and, in January 2019, Capua BioServices, which provides microbial fermentation services.
To run the acquired plant, which mainly produces Rifampicin and its derivative, Olon has set up a new company Olon API India, headquartered in Mumbai. The products are used to treat several types of bacterial infections, including tuberculosis.
The Mahad site supplies products to Sandoz, a division of Swiss drugmaker Novartis, and the companies have agreed a long-term contract to guarantee a continuous supply of products from the plant. The facility employs approximately 270 staff.
The Italian CDMO said it intends to invest in the site and pursue business development opportunities to optimize the plant’s utilization and expand its customer base.
Olon employs about 2,000 people at 10 manufacturing sites worldwide (eight in Italy, and one each in Spain and the US, turning over $400 million in 2018.
Photo: © Olon
Olon has closed the acquisition of a generics API manufacturing facility in Mahad, India.
For more information visit www.chemanager-online.com/en